ASCO 2022 | ASCO 2022: DESTINY-Breast04, PALOMA-2, rEECur

Abhenil Mittal, MD, DM, Princess Margaret Cancer Center, Toronto, Canada, reflects on key updates from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including the results from the DESTINY-Breast04 trial (NCT03734029) which demonstrated a survival benefit with the use of trastuzumab deruxtecan in pre-treated patients with HER2-low breast cancer. Dr Mittal also highlights the final overall survival results from PALOMA-2 (NCT01740427), which evaluated palbociclib + endocrine therapy in first-line metastatic breast cancer. Finally, Dr Mittal talks on the Phase III rEECur trial which demonstrated improved outcomes with the use of high-dose ifosfamide when compared to topotecan/cyclophosphamide in patients with Ewing sarcoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.